Biotech News Brief

Biotech news for Saturday, September 26, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.

Neutral · 50/100Sep 23, 6:04 PM EDT

Arcturus Reports Positive Interim Phase 2 Data for ARCT-810 in OTC Deficiency

ARCT

Arcturus Therapeutics announced interim Phase 2 results showing ARCT-810 reduced and/or maintained first morning fasting ammonia within normal range in patients with OTC deficiency. The candidate also reduced glutamine levels. These positive data support furth…

  • ▹Positive interim Phase 2 data for ARCT-810 in OTC deficiency, but early-stage and single-asset risk
  • ▹No regulatory or commercial catalysts yet; manufacturing and reimbursement unproven
Neutral · 50/100Sep 23, 4:59 PM EDT

Viking Therapeutics Seeks $400 Million Through Stock and Convertible Note Offerings

VKTX

Viking Therapeutics announced plans to raise $400 million via separate public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032. The company also plans to grant underwriters an option to purchase additional shares.…

  • ▹Dilution risk from $400M combined offering pressures narrative score
  • ▹Clinical-stage metabolic/endocrine platform with no commercial revenue
← Back to the latest News Brief